Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro

Clinical and Experimental Immunology

Volumn 148, Issue 1, 2007, Pages 136-145

  Li, G ^a   Zeng, Y ^a   Chen, X ^a   Larmonier, N ^a   Sepassi, M ^a   Graner, M W ^b   Andreansky, S ^a   Brewer, M A ^a   Katsanis, E ^a,c  

^a UNIVERSITY OF ARIZONA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer vaccine; Chaperone rich cell lysate (CRCL); Dendritic cell (DC); Heat shock protein (HSP); Ovarian cancer

Indexed keywords

CANCER VACCINE; CHAPERONE RICH CELL LYSATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; HLA A2 ANTIGEN; INTERLEUKIN 12; UNCLASSIFIED DRUG;

ARTICLE; CELL LYSATE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DRUG POTENCY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; OVARY TUMOR; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HLA-A2 ANTIGEN; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOCYTES, TUMOR-INFILTRATING; MOLECULAR CHAPERONES; OVARIAN NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 33847615131     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03323.x     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-30.
2. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC. The biology of ovarian cancer. Semin Oncol 1998; 25:281-304.
3. Rabban JT, Bell DA. Current issues in the pathology of ovarian cancer. J Reprod Med 2005; 50:467-74.
4. Janetzki S, Palla D, Rosenhauer V et al. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 2000; 88:232-8.
5. Pilla L, Patuzzo R, Rivoltini L et al. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother 2006; 55:958-68.
6. Mazzaferro V, Coppa J, Carrabba MG et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 2003; 9:3235-45.
7. Oki Y, Younes A. Heat shock protein-based cancer vaccines. Exp Rev Vaccines 2004; 3:403-11.
8. Li Z. Priming of T cells by heat shock protein-peptide complexes as the basis of tumor vaccines. Semin Immunol 1997; 9:315-22.
9. Srivastava PK, Amato RJ. Heat shock proteins: the 'Swiss Army knife' vaccines against cancers and infectious agents. Vaccine 2001; 19:2590-7.
10. Basu S, Srivastava PK. Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J Exp Med 1999; 189:797-802.
11. Graner M, Raymond A, Romney D et al. Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma. Clin Cancer Res 2000; 6:909-15.
12. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997; 278:117-20.
13. Udono H, Srivastava PK. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol 1994; 152:5398-403.
14. Park JE, Facciponte J, Chen X et al. Chaperoning function of stress protein grp170, a member of the hsp70 superfamily, is responsible for its immunoadjuvant activity. Cancer Res 2006; 66:1161-8.
15. Manjili MH, Wang XY, Chen X et al. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J Immunol 2003; 171:4054-61.
16. Belli F, Testori A, Rivoltini L et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002; 20:4169-80.
17. Rivoltini L, Castelli C, Carrabba M et al. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. J Immunol 2003; 171:3467-74.
18. Zeng Y, Graner MW, Katsanis E. Chaperone-rich cell lysates, immune activation and tumor vaccination. Cancer Immunol Immunother 2006; 55:329-38.
19. Graner M, Raymond A, Akporiaye E, Katsanis E. Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines. Cancer Immunol Immunother 2000; 49:476-84.
20. Graner MW, Zeng Y, Feng H, Katsanis E. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother 2003; 52:226-34.
21. Zeng Y, Feng H, Graner MW, Katsanis E. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood 2003; 101:4485-91.
22. Feng H, Zeng Y, Graner MW, Likhacheva A, Katsanis E. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood 2003; 101:245-52.
23. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995; 181:2109-17.
24. Romani N, Gruner S, Brang D et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180:83-93.
25. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-8.
26. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat Immunol 2002; 3:999-1005.
27. Srivastava PK, Udono H, Blachere NE, Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 1994; 39:93-8.
28. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002; 20:395-425.
29. Watts C. The exogenous pathway for antigen presentation onmajor histocompatibility complex class II and CD1 molecules. Nat Immunol 2004; 5:685-92.
30. Ackerman AL, Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 2004; 5:678-84.
31. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392:86-9.
32. Inaba K, Turley S, Yamaide F et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 1998; 188:2163-73.
33. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001; 14:303-13.
34. Lenahan C, Avigan D. Dendritic cell defects in patients with cancer: mechanisms and significance. Breast Cancer Res 2006; 8:101.
35. Satthaporn S, Robins A, Vassanasiri W et al. Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol Immunother 2004; 53:510-8.
36. Ramirez SR, Singh-Jasuja H, Warger T et al. Glycoprotein 96-activated dendritic cells induce a CD8-biased T cell response. Cell Stress Chaperones 2005; 10:221-9.
37. Li Z, Qiao Y, Liu B et al. Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res 2005; 11:4460-8.
38. Graner MW, Likhacheva A, Davis J et al. Cargo from tumor-expressed albumin inhibits T-cell activation and responses. Cancer Res 2004; 64:8085-92.